Cargando…
Cellular Immune Response after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Hematopoietic stem cell transplant (HSCT) recipients have a high risk of developing primary varicella-zoster virus (VZV) infection and reactivation. VZV vaccination may prevent infection and reactivation. In the current study, recipients of allogeneic HSCT (34 females, 45 males) were vaccinated with...
Autores principales: | Koldehoff, Michael, Horn, Peter A., Lindemann, Monika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143460/ https://www.ncbi.nlm.nih.gov/pubmed/35632565 http://dx.doi.org/10.3390/vaccines10050809 |
Ejemplares similares
-
Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients
por: Lindemann, Monika, et al.
Publicado: (2022) -
Cellular and Humoral Immunity after the Third Vaccination against SARS-CoV-2 in Hematopoietic Stem-Cell Transplant Recipients
por: Thümmler, Laura, et al.
Publicado: (2022) -
36. Safety and Reactogenicity of the Adjuvanted Recombinant Zoster Vaccine after Allogeneic Hematopoietic Stem Cell Transplantation
por: Baumrin, Emily, et al.
Publicado: (2020) -
Humoral and Cellular Vaccination Responses against SARS-CoV-2 in Hematopoietic Stem Cell Transplant Recipients
por: Lindemann, Monika, et al.
Publicado: (2021) -
Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant Recipients
por: Koldehoff, Michael, et al.
Publicado: (2023)